Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer

Starting soon

Conditions studied: Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma

In brief

How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing. Substantial variation exists among patients in their tumor response to the same conversion therapy regimen, and current pretreatment imaging assessment does not adequately capture this inter-individual variability. We hypothesize that baseline tumor viscoelastic parameters measured by three-dimensional magnetic resonance elastography (3D-MRE) differ substantially across patients, and that this inter-individual heterogeneity may be associated with differential response to conversion therapy. This study aims to prospectively evaluate the association between baseline 3D-MRE-derived tumor viscoelastic parameters and pathological response as well as surgical conversion outcomes across patients with liver cancer receiving conversion therapy.

Key facts

Study ID

NCT07716345

Run by

Second Affiliated Hospital of Xi'an Jiaotong University

People needed

100

Starts

2026-10-01

Expected to finish

2030-10-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years
• Pathologically or radiologically confirmed diagnosis of initially unresectable liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis)
• Planned to receive conversion therapy with the intent of achieving surgical resectability
• Child-Pugh class A or B liver function (for patients with primary liver cancer)
• ECOG performance status 0-1
• At least one measurable lesion per RECIST 1.1
• Able to undergo 3D-MRE examination prior to conversion therapy
• Provision of signed and dated informed consent

You may not qualify if…

• Contraindication to MRI
• Child-Pugh class C liver function (for patients with primary liver cancer)
• Uncontrolled ascites, hepatic encephalopathy, or variceal bleeding within 3 months prior to enrollment
• Other concurrent active malignancy
• Severe comorbidities precluding conversion therapy or surgery
• Pregnant or breastfeeding women
• Anticipated poor compliance with repeated MRE examinations or follow-up

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.